更新于：2024-11-01

Asperger Syndrome

阿斯伯格综合症

更新于：2024-11-01

基本信息

别名

Asperger、Asperger Disease、Asperger Diseases

+ [40]

简介

A disorder beginning in childhood whose essential features are persistent impairment in reciprocal social communication and social interaction, and restricted, repetitive patterns of behavior, interests, or activities. These symptoms may limit or impair everyday functioning. (From DSM-5)

关联

项与阿斯伯格综合症相关的药物

Aripiprazole

阿立哌唑

靶点

5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor

作用机制

5-HT1A receptor激动剂 [+3]

在研机构

Accord Healthcare SLU [+11]

原研机构

Otsuka Holdings Co., Ltd.

在研适应症

自闭症谱系障碍 [+11]

非在研适应症

急性精神分裂症 [+16]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2002-11-15

Memantine hydrochloride

盐酸美金刚

靶点

NMDA receptor

作用机制

NMDA receptor拮抗剂

在研机构

KRKA dd [+11]

原研机构

Merz Pharma GmbH & Co. KGaA

在研适应症

阿尔茨海默症 [+2]

非在研适应症

躁动 [+14]

最高研发阶段批准上市

首次获批国家/地区

德国

首次获批日期2000-08-11

Risperidone

利培酮

靶点

5-HT2A receptor x D2 receptor

作用机制

5-HT2A receptor拮抗剂 [+1]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1993-12-29

127

项与阿斯伯格综合症相关的临床试验

DRKS00034964 / SuspendedN/AIIT

Use of the Interactive Drawing Test to assess reciprocity in social interaction in adults with and without ASD, taking gender differences into account

开始日期2024-10-15

申办/合作机构-

DRKS00032847 / RecruitingN/AIIT

Recalibration of audio-visual synchronicity and its impact on perception in children and adolescents with autism spectrum disorder - Multisensory training in children and adolescents with autism spectrum disorder (MUTRAKiA)

开始日期2024-01-16

申办/合作机构-

NCT05509231 / Not yet recruitingN/AIIT

Effects of a Multimodal Exercise Program for Children With Autistic Spectrum Disorder (ASD) on Cognitive and Motor Abilities: Part III

Exploring the effects of an exercise program for children ages 6 -26 years old who have been diagnosed with autism spectrum disorder and neurotypical children respond to high-intensity whole body exercise interventions (Group 1), training using a sensory glove and armband (Group 2), no-intervention control (waitlist control) (Group 3). Approximately 50 children and adolescents will volunteer to participate in this program with participants parents' (or legal guardians') permission. This study will be conducted at an off-site pediatric occupational therapy facility Inclusive Sports and Fitness, Inc. (ISF).

开始日期2024-01-12

申办/合作机构

New York Institute of Technology

100 项与阿斯伯格综合症相关的临床结果

登录后查看更多信息

100 项与阿斯伯格综合症相关的转化医学

登录后查看更多信息

0 项与阿斯伯格综合症相关的专利（医药）

登录后查看更多信息

1,948

项与阿斯伯格综合症相关的文献（医药）

2024-09-01·History of Psychiatry

‘Early childhood autism, Asperger type’, by H. Asperger (1982)

Article

作者: Rebecchi, Kevin

After his 1944 thesis, Asperger continued to write about autism, but none of these texts have been translated. At a time when autism spectrum disorder faces many challenges (e.g. the nature and measurement of autism), this text tells us more about the particular population that Asperger worked with. He describes sensitive, intelligent, creative and rational children, a far cry from the Wing triad. Moreover, ‘Asperger’s Syndrome’ was introduced after he had died, was included in the DSM-IV in 1994 and was omitted from the DSM-5 in 2013. The question posed by this last text, written before his death, is whether Asperger’s descriptions of autistic children are really part of the autism spectrum disorder or whether they are outside the pathological field.

2024-08-26·Cureus

Clinical Profile of Neurodevelopmental Disorders in Children at a Tertiary Care Center

Article

作者: Salunkhe, Shradha ; Pande, Vineeta ; Bahal, Mridu ; Kale, Shivani ; Shaligram, Ruhi ; Dua, Jasleen ; Garlapati, Srinija ; Kumar, Gaurav ; Mane, Shailaja ; Gupta, Aryan

Background Neurodevelopmental disorders (NDDs) encompass intricate interactions among genetic, brain, cognitive, emotional, and behavioral processes. These disorders, which are influenced by hereditary and environmental factors, impair personal, social, intellectual, or occupational functioning. Typically emerging early in life, NDDs include conditions such as attention deficit hyperactivity disorder (ADHD), intellectual disability, autism spectrum disorders (ASDs), vision and hearing impairments, motor disorders, and specific learning disabilities. Children from impoverished and low-income neighborhoods are particularly vulnerable. The lack of comprehensive health data and public awareness about these conditions results in limited information regarding the prevalence of neurological illnesses in developing countries. India, with its large and ethnically diverse population, exemplifies this gap. Methods It is a prospective study to detect the prevalence and risk factors of neurodevelopmental disorders in children aged six months to nine years at a tertiary care center. Patient details, clinical findings, and relevant history were recorded on a pre-designed pro forma and analyzed statistically. Results Among the 1000 children in the study, 91 (9.1%) tested positive for NDDs. Among the 91 children who tested positive for NDD, the highest frequency is in the three to four years age group (17.6%), males were found to be in a higher ratio with 75.82%, with the male: female ratio being 3:1. Among the 91 children with NDD, intellectual disability was the most common disorder (20.9%), followed by ADHD (17.6%) and vision impairment (14.3%). Autism spectrum disorders, including autism and Asperger syndrome, and communication disorders, including stuttering and speech disorders, accounted for 13.2% each. Hearing loss was seen in 9.9% of children and multiple disorders were seen in 8.8% of the children from among 91 children. Conclusion Neurodevelopmental disorders are common and often coexist with other conditions. Children from low-income backgrounds are more affected. This study provides valuable insights into the prevalence and characteristics of NDDs in a specific population.

2024-07-01·The American Journal of Occupational Therapy

Affective Contact in Autism: A Phenomenological Study of the Emotional Experiences of Autistic Adults

Article

作者: Dallman, Aaron

AbstractImportance: Since the first descriptions of autism, difficulties with affective contact (e.g., interpersonal exchanges of feelings between individuals) have been considered a common feature of autism spectrum disorder, and these difficulties frequently manifest in occupational therapy interventions.Objective: To (1) explore how autistic young adults describe their emotions and (2) suggest ways to improve the affective contact between autistic clients and their therapists.Design: Virtual focus group interviews.Setting: Online (Qualtrics) survey and Zoom focus groups.Participants: Autistic adults (N = 24) who met the following inclusion criteria: self-reported diagnosis of autism spectrum disorder or Asperger syndrome, age 18–35 yr, able to understand English, and able to participate in a focus group or individual interview using verbal or written communication.Results: Two themes were noted and are presented in this article: (1) Autistic people experience complex emotions and (2) autistic people’s emotions are often (mis)measured and (mis)understood.Conclusions and Relevance: The findings indicate that autistic people experience diverse, complex, and intense emotions and that these are connected to occupation. This suggests that occupational therapists must be attuned to the emotional dimension of occupation when working with autistic clients and that autistic clients may benefit from the use of embodied language to reference their emotions. Occupational therapists can help autistic clients recognize their bodily changes when experiencing emotions and to better identify and regulate their emotions. The results also show that there were many cases nonautistic people misinterpreted the emotions of autistic people on the basis of their facial expressions or words.Plain-Language Summary: This article provides information about the emotional experiences of autistic people. The study found that autistic people experience complex emotions and that those emotions are often misinterpreted or misunderstood. The author provides information on how occupational therapists can use a neurodiversity-affirming and person-centered approach to support the emotional experiences of people in the autism community.Positionality Statement: In this article, identity-first language is used when referring to autistic adults. This deliberate choice aligns with the principles of the neurodiversity-affirming movement. Autistic self-advocates have indicated a preference for this style of language over person-first language. The author would also like to acknowledge their positionality. As both a neurodivergent researcher and a self-advocate for the disabled community, this style of language aligns with their own experiences of and beliefs about their disability.

项与阿斯伯格综合症相关的新闻（医药）

2023-02-06

·生物谷

STTT：突破！川大/首医大团队发现自闭症谱系障碍的新风险基因，抗炎药和催产素类似物是潜在干预方案

该研究发现了一个新的ASD风险基因SCGN，而且发现SCGN的缺失会破坏催产素信号，并异常激活炎症，最终导致导致类似自闭症的行为、损害大脑发育，而催产素和抗炎药物或可以减弱由SCGN缺失引起的ASD相每年的4月2日，是世界“自闭症儿童关爱日”，这是一群被称为“来自星星的孩子”：世界在他们面前，也不在他们面前，世界倒映在他们眼里，他们却什么都看不见，就像天上的星星，独居在自己的世界里。自闭症谱系障碍（ASD）是一组以交流和社会互动障碍为特征的异质神经发育疾病，包括自闭症、阿斯伯格综合征、不典型自闭症以及儿童瓦解性精神障碍。2021年，美国疾病控制与预防中心（CDC）发布的报告显示：每44名8岁儿童中就有一名（2.3%）被确认患有ASD[1]。 ASD患者主要表现为沟通和社会互动障碍，以及重复或受限的感觉运动行为。除了这些核心症状外，可能还会出现发育迟缓、智力障碍、焦虑、抑郁、胃肠道和免疫系统疾病等。鉴于ASD的临床特征异质性，一直没有针对这种疾病的有效治疗方法，现有的ASD治疗药物不仅效果不佳，而且还会产生巨大的副作用，因此进一步了解ASD的发病机制对于开发新的治疗策略是必不可少的。近日，由四川大学贾大、张小虎、莫显明，以及首都医科大学李巍共同领衔的研究团队，在Signal Transduction and Targeted Therapy在线发表了最新研究成果。在这项研究中，他们发现突触传递的调节因子促泌素（SCGN）是ASD的一个新的风险基因，SCGN缺失通过破坏激活大脑中的促炎反应和催产素信号导致自闭症行为，而用消炎药和催产素类似物治疗SCGN缺失的动物则可以纠正自闭症行为[2]。文章首页截图为了识别潜在的ASD风险基因，研究人员首先对ASD先证者（对ASD遗传性状进行家系调查时，其家系中第一个被确诊的那个人）及其父母进行了全外显子组测序，在参与研究的168例病例中，有2例确定存在SCGN突变（ASD0010和ASD0014）。这两名患者都表现出典型的ASD核心特征，包括通过CABS、ABC和CARS评分衡量的沟通和社交缺陷。此外，根据Gesell发育量表，这两名SCGN突变的ASD患者还表现出严重的发育迟缓。 SCGN的突变与ASD有关接下来研究人员使用CRISPR/Cas9基因编辑技术，生成了scgn基因缺失的斑马鱼模型，以确定scgn基因在社会行为和神经元发育中的作用。结果发现相比于scgn+/−、scgn−/−基因型的斑马鱼，scgn+/+基因型的斑马鱼的社交持续时间明显更长，表现出更强的社会凝聚力，也就是说scgn基因纯合或杂合缺失会导致斑马鱼的自闭症样行为。此外，研究人员还观察到scgn基因缺失损坏斑马鱼的大脑发育，与scgn+/+胚胎相比，scgn−/−胚胎的头部尺寸显著减小，反映斑马鱼大脑发育的的眼长和眼距也体现出类似的结果：与scgn+/+组相比，scgn−/−胚胎表现出明显更小的眼睛，眼睛之间的距离更短。 scgn缺失损害斑马鱼的神经元发育那么scgn缺失是如何导致ASD的呢？为了回答这个问题，研究人员使用RNA-seq比较了scgn+/+和scgn−/−的斑马鱼大脑和小鼠下丘脑的基因表达谱差异。基因集富集分析（GSEA）显示，两者的差异表达基因（DEGs）主要富集在神经递质受体活性等通路。有趣的是，在炎症和先天免疫反应信号等多种免疫调节通路中也有富集。为了进一步证实上述观察结果，研究人员进行定量RT-PCR比较了scgn缺失小鼠模型中免疫相关的多个基因的表达，结果发现scgn缺失导致促炎基因IL-6和TNF的上调。ELISA结果也表明，scgn−/−小鼠中IL-6和IL-1β蛋白水平升高。也就是说，scgn基因缺失会改变免疫反应，导致异常炎症。 scgn缺失会改变免疫反应由于scgn蛋白通常调节激素分泌，因此研究人员进一步比较了scgn+/+和scgn−/−小鼠的血清代谢组学差异。综合代谢组学和转录组分析的结果，研究人员发现，scgn缺失导致催产素信号和神经活性配体-受体相互作用通路中断，影响催产素通路中许多基因如Oxt、Ppp3cb和Plcb3的表达。此外，与年龄匹配的scgn+/+组相比，scgn+/−和scgn−/−斑马鱼大脑中的催产素mRNA和蛋白质水平均显著降低，scgn+/−和scgn−/−斑马鱼的血清催产素水平相对于scgn+/+对照组降低了31%。总之，这些数据表明，scgn的功能缺失导致斑马鱼和小鼠催产素减少。 scgn缺失影响催产素分泌那么抗炎药物的使用和催产素的补充是否可以挽救scgn缺失导致的异常炎症和神经元发育障碍呢？研究人员于是选择了两种抗炎药物地塞米松和阿司匹林，以及一种半衰期延长的催产素合成物卡贝催产素处理ASD动物模型。可以看到，0.5μM或1μM卡贝催产素处理1天后，scgn+/−和scgn−/−斑马鱼胚胎的IL-1β的表达明显减弱，其表达与未处理对照组相似，抗炎药地塞米松和阿司匹林处理也强烈降低了scgn+/−和scgn−/−斑马鱼中IL-1β的表达。此外，scgn缺失所导致的ASD表型也可以被上述三种药物改善，其中高剂量的卡贝催产素和阿司匹林表现出最显著的改善效果，1μM的卡贝催产素处理使近2/3的scgn−/−斑马鱼的社会互动恢复到正常对照的水平，而10μM阿司匹林处理则可以使1/3-1/2的斑马鱼的社会互动恢复到正常对照组水平。催产素类似物、抗炎药物可拮抗斑马鱼scgn缺失导致的ASD 总的来说，该研究发现了一个新的ASD风险基因SCGN，而且发现SCGN的缺失会破坏催产素信号，并异常激活炎症，最终导致导致类似自闭症的行为、损害大脑发育，而催产素和抗炎药物或可以减弱由SCGN缺失引起的ASD相关缺陷。上述研究提示，催产素和抗炎药物是SCGN缺乏患者的潜在治疗方法，在精准医疗时代，这些机制的阐明将有助于开发针对ASD的个性化治疗手段，拓宽目前有限的ASD治疗干预方法的选择。同时，这一研究成果也提示根据ASD患者的具体发病机制来提供不同的治疗手段是至关重要的，这可以极大地提高治疗的成功率。参考文献： [1] Jiang, Chen-Chen et al. “Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications.” Signal transduction and targeted therapy vol. 7,1 229. 11 Jul. 2022 [2] Liu, Zhe et al. “SCGN deficiency is a risk factor for autism spectrum disorder.” Signal transduction and targeted therapy vol. 8,1 3. 2 Jan. 2023

生物类似药基因疗法

2022-09-16

·药明康德

前沿 | 根本性治疗自闭症！多款老药被发现具调控自闭症相关基因潜力

▎药明康德内容团队编辑自闭症谱系障碍（ASD）是一种广泛性的神经发展障碍，每位患者的临床表现形式和严重程度差异很大，但主要的核心症状是患者在社会沟通与互动上的缺陷，并可能有受限、重复的行为模式，例如阿斯伯格综合征便是属于ASD的一种。在美国每54人中约有1位ASD患者。病患可能伴有像是睡眠障碍、焦虑、沮丧、过动或攻击性行为等精神类症状。然而直至今日仍没有直接针对患者社交障碍症状的获批药物，许多目前治疗ASD的药物多是针对患者焦躁、多动与自残等非核心症状进行治疗，且常造成许多严重的副作用。然而近日由挪威奥斯陆大学科研团队发表的论文发现，许多现有批准药物具有潜力作用于ASD特异性遗传变异，有望改善临床ASD核心症状的治疗。为了在找出那些可能改善ASD核心症状的现有批准药物，研究人员的策略是先找寻与ASD相关的基因变异，接着再从批准药物群中识别那些可以调控这些基因表达的药物。ASD是由多个基因变异共同造成的遗传性疾病。因此为了识别与ASD相关的基因变异，研究人员首先对分别包含1.2万、1.8万患者的两项大型基因测序结果进行分析，在与多达2.8万健康对照组个体的测序结果进行比较后，研究人员发现207个基因与ASD的产生相关。为了解哪些现有药物可能可以调控这些基因，科学家通过药物-基因相互作用数据库（DGIdb）对这些ASD相关基因进行分析。此开源数据库能够提供不同基因与其已知或潜在药物关联的信息。研究人员发现有439个获批药物与其中68个ASD相关基因产生相互作用。接着通过使用Broad研究所开发的Connectivity Map数据库以及另一项称之为MetaXcan的开源软件，研究人员可以知道这些药物如何改变ASD相关基因的表达量，并识别出那些调控基因方式与ASD所引起基因表达异常负相关的药物。经过这一系列分析，研究人员发现了可能可以治疗ASD核心症状的4种现有药物，分别为孕激素避孕药屈螺酮（drospirenone）、女性激素黄体酮（progesterone）、多巴胺D2受体激动剂溴隐亭（bromocriptine）以及腹泻药物洛哌丁胺（loperamide，商品名Imodium）。值得一提的是，所发现的四种药物其药理机制皆与ASD的症状有相关联。例如，屈螺酮可通过阻断睾酮与雄激素受体结合来抑制其作用，而之前曾有研究发现睾酮水平上升与ASD患者的社会沟通障碍有正相关。另有科学家曾提出假说，认为怀孕时母体的低黄体酮含量可用以预测ASD的产生，因此黄体酮可能可被用以治疗ASD。而多巴胺受体激动剂溴隐亭则在1990年代初在ASD的试验中展现积极结果，可在一定程度上改善患者的注意力相关症状。重要的是，在近年来阿片类药物被发现除了已知的镇痛效果与作用于大脑奖赏系统外，亦被发现与调节人体社会行为有关联，有实验证明不表达阿片类受体的小鼠具有与人类ASD患者相似的社会行为变化。这些研究让μ阿片类受体（mu-opioid receptor）激动剂洛哌丁胺被认为是其中最有可能具逆转ASD相关基因变异症状的药物。虽然此篇论文所发现的药物与自闭症相关通路有一定关联，但仍需进行进一步的实验与最终临床试验，才能证实这些药物在调节相关基因变化与改善ASD社会沟通等核心症状的效用。让我们期待这些接续试验会有积极结果，为ASD患者尽快带来根本性治疗的获批药物。药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息参考资料：[1] Koch E. et al. (2022) Drug repurposing candidates to treat core symptoms in autism spectrum disorder. Front. Pharmacol. 13:995439 DOI: 10.3389/fphar.2022.995439[2] Gene interaction analysis predicts existing drugs that could be repurposed for autism. Retrieved September 16, 2022 from https://www.fiercebiotech.com/research/gene-interaction-analysis-predicts-existing-drugs-could-be-repurposed-autism[3] 自闭症谱系障碍. Retrieved September 16, 2022 from https://www.msdmanuals.cn/home/children-s-health-issues/learning-and-developmental-disorders/autism-spectrum-disorders免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

2021-03-05

·GlobeNewswire

Autism Spectrum Disorder Therapeutics Market Projected to Hit USD 4,612.1 Million and Surge at 4.3% CAGR by 2026; Awareness Campaigns Conducted to Spread Awareness Regarding the Condition to Propel Growth, Says Fortune Business Insights™

Pune, India, March 04, 2021 (GLOBE NEWSWIRE) -- According to a report published by Fortune Business Insights, titled, “ Autism Spectrum Disorder Therapeutics Market ”: Global Market Analysis, Insights and Forecast, 2018-2026,” the global market is likely to reach US$ 4,612.1 Mn by 2026 owing to the rising incidence of autism spectrum disorder worldwide. The report provides valuable insights into the global market trends and factors that are directly affecting the growth of the market. As per the report, the global autism spectrum disorder therapeutics market was worth US$ 3,293.0 Mn in 2018. Considering the increasing awareness programs regarding this particular disorder and less availability of treatment options, the global market is expected to rise at a moderate CAGR of 4.3% during the forecast period (2019-2026). The report further states that the number of children diagnosed with autism is increasing day by day across the globe. This, combined with favorable reimbursement scenario, will increase the demand for applied behavioral analysis therapies. Such therapies aid in improving learning and physical disabilities in autistic children. Furthermore, FDA approvals of numerous medicines that are used to manage autism spectrum disorder are expected to propel the global autism spectrum disorder therapeutics market during the forecast period. Request a Sample Copy of the Research Report: Autistic Disorder Segment to Witness Growth Owing to the Rising Prevalence of the Disease The global autism spectrum disorder therapeutics market is grouped into drug therapy and communication and behavioral therapy in terms of treatment type. Amongst these, the communication and behavioral therapy segment was in the leading position in the global market. Fortune Business Insights predicts that it will retain its position throughout the forecast period. In terms of type, the autism spectrum disorder therapeutics market is classified into Asperger syndrome, autistic disorder, pervasive development disorder, and others. Out of these, the autistic disorder segment procured the highest autism spectrum disorder therapeutics market share in the year 2018. It is anticipated to witness significant growth in the coming years. This growth is attributed to the increasing prevalence of this disorder. For more information in the analysis of this report, visit: Fusion Autism Center Opens its New Therapy Center to Provide Pediatric Services Several renowned market players have begun investing huge sums in the research and development of advanced and effective drugs for the treatment of autism spectrum disorder. This will contribute to the global autism spectrum disorder therapeutics market growth in the coming years. Below are three latest initiatives that have been recently taken by the prominent market players to drive global market sales. Fusion Autism Center (FAC), a mental health service provider, based in the U.S.A., announced in February 2019 that it has successfully expanded its center-based services of Applied Behavioral Analysis therapy for kids on the autism spectrum. The new center is built in Augusta so that it would provide much-needed services to the communities with special needs residing in the area. Apart from that, FAC has its centers in Roswell, Woodstock, Cumming, Peachtree, and Duluth. Quick Buy Autism Spectrum Disorder Therapeutics Market Research Report: Q BioMed Inc., a prominent developer of biomedical assets, based in New York, announced in June 2018 that it has applied for Orphan Drug status with European and the U.S. regulators for QBM-001, the company’s pediatric autism drug. F. Hoffmann-La Roche Ltd., a multinational healthcare company, headquartered in Switzerland, announced that the FDA has approved Breakthrough Therapy Designation for its oral medication balovaptan in January 2018. The investigational oral medicine has the potential to improve communication and interaction abilities of those affected with autism spectrum disorder. Have Any Query? Ask Our Experts: List of the Companies Profiled in the Global Market: Applied Behavior Consultants, Allergan, Pfizer Inc., Q BioMed Inc, Fusion Autism Center, AstraZeneca, Hopebridge, LLC., Johnson & Johnson Services, Inc., Behavior Innovations, Eli Lilly and Company, Otsuka Holdings Co. Ltd., other prominent market players. Get your Customized Research Report: Detailed Table of Content: Introduction Research Scope Market Segmentation Research Methodology Definitions and Assumptions Executive Summary Market Dynamics Market Drivers Market Restraints Market Opportunities Key Insights Prevalence of Autism Spectrum Disorder for Key Countries/Region Recent Industry Developments Such As Partnerships, Mergers, & Acquisitions Regulatory Framework by Key Countries Global Reimbursement Scenario and Economic Cost Burden for the Treatment of Autism Spectrum Disorder by Key Countries/Region Global Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2015-2026 Key Findings / Summary Market Analysis, Insights and Forecast – By Type Autistic Disorder Asperger Syndrome Pervasive Developmental Disorder Others Market Analysis, Insights and Forecast – By Treatment Type Communication & Behavioral Therapies Applied behavior analysis (ABA) Speech & Language Therapy Occupational Therapy Others Drug Therapies Antipsychotic Drugs SSRIS Stimulants Sleep Medications Others Market Analysis, Insights and Forecast – By Region North America Europe Asia pacific Latin America Middle East & Africa TOC Continued…!! Have a Look at Related Reports: MicroRNA Market Size , Share & Covid-19 Impact Analysis, By Product (Instruments and Kits & Reagents) By Application (Isolation & Purification, Detection & Quantification, Disease Diagnostics, and Others) and By End User (Pharma & Biotech Companies, Academic & Research Institutes, Healthcare Facilities, and Others), Regional Forecast, 2020-2027 Nurse Call Systems Company Size, Share & Industry Analysis, By Technology (Wired, Wireless), By Product (Basic Button Based Systems, Mobile Integrated Systems, IP Based Systems, Others), By End-user (Hospitals and Clinics, Assisted Living and Nursing Centres, Home Care Setting, Others), and Regional Forecast, 2019 – 2026 Telerehabilitation Market Size, Share and Covid-19 Impact Analysis, By Type (Products, Services), By Application (Occupational Therapy, Physical Therapy, Chronic Diseases, and Others), By End-User (Healthcare Facilities and Homecare); and Regional Forecast, 2020-2027 Active Wound Care Market Share and Industry Analysis by Product Type (Biological Skin Equivalents, Growth Factors, Biological Dressings, Others), By Indication (Diabetic Foot Ulcers, Pressure Ulcers, Lower Limb Ulcers), By End User (Hospitals, Clinics, Home Care Settings), and Regional Forecast 2018-2025 About Us: Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us: Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India. Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: sales@fortunebusinessinsights.com Fortune Business Insights™ LinkedIn | Twitter | Blogs

孤儿药突破性疗法并购